Maltzman Henrik, Omae Masami, Klevebro Fredrik, Baldaque-Silva Francisco, Rouvelas Ioannis
Department of Clinical Science, Intervention and Technology (CLINTEC), Division of Surgery and Oncology, Karolinska Institutet, Hälsovägen 13, 141 57, Huddinge, Stockholm, Sweden.
Department of Upper Abdominal Diseases, Karolinska University Hospital, Stockholm, Sweden.
Pilot Feasibility Stud. 2025 Jan 3;11(1):1. doi: 10.1186/s40814-024-01584-3.
The standard treatment for advanced gastric cancer without metastasis is gastrectomy in combination with chemotherapy. Some patients cannot tolerate such treatment because of old age or comorbidities. In this study, we want to test the feasibility of Laparoscopic and Endoscopic Cooperative Surgery (LECS) as a less invasive treatment option. In LECS, the tumor margin is marked endoscopically, followed by surgical removal under endoscopic guidance. Currently, LECS is primarily used in Asian countries as a treatment for gastrointestinal stromal cell tumors.
The study will be conducted as a prospective single-center, feasibility trial. The primary objective will be the safety of LECS, defined as Clavien-Dindo score ≥ III. The secondary objectives will be any complications, postoperative bleeding/perforation, operation time, radicality, mortality, hospital stay, and health-related quality of life. The inclusion criteria will be patients with gastric cancer cT2-T4aN0M0, Borrman type 1-2 < 5 cm, or type 3 < 2 cm that the tumor board assesses as not fit for gastrectomy. Exclusion criteria will be Borrman type 4 and lesions in the cardia. The patients will be followed up with an outpatient appointment 30 days after the procedure.
LECS is a promising treatment option for patients with gastric cancer who cannot tolerate gastrectomy. Compared to gastrectomy, LECS is a less invasive procedure with a documented low complication rate. No previous prospective studies have been conducted to evaluate LECS for advanced gastric cancer.
ClinicalTrials.gov identifier: NCT06105515. Registered 23 October 2023. https://clinicaltrials.gov/study/NCT06105515?cond=Gastric%20Cancer&term=NCT06105515&aggFilters=status:not%20rec&rank=1.
晚期无转移胃癌的标准治疗方法是胃切除术联合化疗。一些患者由于年龄或合并症无法耐受这种治疗。在本研究中,我们想测试腹腔镜与内镜联合手术(LECS)作为一种侵入性较小的治疗选择的可行性。在LECS中,肿瘤边缘在内镜下标记,然后在内镜引导下手术切除。目前,LECS主要在亚洲国家用于治疗胃肠道间质细胞瘤。
本研究将作为一项前瞻性单中心可行性试验进行。主要目标将是LECS的安全性,定义为Clavien-Dindo评分≥III级。次要目标将是任何并发症、术后出血/穿孔、手术时间、根治性、死亡率、住院时间以及与健康相关的生活质量。纳入标准将是cT2-T4aN0M0期胃癌患者,Borrmann 1-2型肿瘤<5 cm,或3型肿瘤<2 cm,肿瘤委员会评估为不适合胃切除术。排除标准将是Borrmann 4型和贲门病变。患者将在手术后30天进行门诊随访。
LECS对于无法耐受胃切除术的胃癌患者是一种有前景的治疗选择。与胃切除术相比,LECS是一种侵入性较小的手术,并发症发生率较低。以前没有进行过前瞻性研究来评估LECS用于晚期胃癌的情况。
ClinicalTrials.gov标识符:NCT06105515。于2023年10月23日注册。https://clinicaltrials.gov/study/NCT0610551�?cond=Gastric%20Cancer&term=NCT06105515&aggFilters=status:not%20rec&rank=1 。